Journal of Antimicrobial Chemotherapy (2002) 49, 479-487
© 2002 The British Society for Antimicrobial Chemotherapy
Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936)
a Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, 61 Colindale Avenue, London NW9 5HT; b Public Health Laboratory, University Hospital, Nottingham NG7 2UH, UK
A survey was conducted of the antimicrobial susceptibilities of 595 Acinetobacter spp. isolated from routine clinical specimens in 54 sentinel laboratories throughout the UK during 2000. Isolates of the Acinetobacter baumannii complex (genomic groups 2, 3 and 13TU; n = 443) were distinguished from other genomic groups (n = 152) by PCR fingerprinting of tDNA spacer regions. MICs of amikacin, cefotaxime, ceftazidime, ciprofloxacin, colistin, gentamicin, imipenem, meropenem, minocycline, piperacillin, piperacillin/tazobactam, rifampicin, sulbactam and tetracycline were determined on IsoSensitest agar and interpreted, wherever possible, using BSAC breakpoints. Tigecycline (GAR-936), a new glycylcycline, was also tested. Resistance to cephalosporins, aminoglycosides and ciprofloxacin was widespread, but carbapenems, colistin, sulbactam, minocycline and tigecycline were each active against >80% of the isolates. Isolates of A. baumannii were more often resistant to cefotaxime, ceftazidime, piperacillin, piperacillin/tazobactam, ciprofloxacin, gentamicin and tetracyclines than those belonging to other genomic groups, but were less often resistant to colistin; no significant differences between genomic groups were noted in the susceptibilities to amikacin, carbapenems, rifampicin or sulbactam. The relative activities of the tetracyclines were minocycline > tigecycline > tetracycline. Thirteen carbapenem-resistant isolates (MICs 8 mg/L; 2.2%) were received from six centres; four centres sent single isolates; one sent three and one sent six. An allele of bla IMP was detected in one of these isolates, but the other 12 isolates either had carbapenemase-independent resistance, or undetectable carbapenemase activity combined with other resistance mechanisms. In conclusion, carbapenems, colistin and minocycline retained greatest activity against the Acinetobacter isolates collected. Tigecycline was less active than minocycline, but both agents overcame most tetracycline resistance.
* Corresponding author. Tel: +44-20-8200-4400; Fax: +44-20-8358-3292; E-mail: nwoodford{at}phls.org.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. M. Livermore, R. Hope, G. Brick, M. Lillie, R. Reynolds, and on behalf of the BSAC Working Parties on Resistanc Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06 J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii55 - ii63. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Capone, S. D'Arezzo, P. Visca, N. Petrosillo, and on behalf of the Gruppo Romano Acinetobacter bauma In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii J. Antimicrob. Chemother., August 1, 2008; 62(2): 422 - 423. [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Moland, D. W. Craft, S.-g. Hong, S.-y. Kim, L. Hachmeister, S. D. Sayed, and K. S. Thomson In Vitro Activity of Tigecycline against Multidrug-Resistant Acinetobacter baumannii and Selection of Tigecycline-Amikacin Synergy Antimicrob. Agents Chemother., August 1, 2008; 52(8): 2940 - 2942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Valentine, D. Contreras, S. Tan, L. J. Real, S. Chu, and H. H. Xu Phenotypic and Molecular Characterization of Acinetobacter baumannii Clinical Isolates from Nosocomial Outbreaks in Los Angeles County, California J. Clin. Microbiol., August 1, 2008; 46(8): 2499 - 2507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y. Peleg, H. Seifert, and D. L. Paterson Acinetobacter baumannii: Emergence of a Successful Pathogen Clin. Microbiol. Rev., July 1, 2008; 21(3): 538 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Karageorgopoulos, T. Kelesidis, I. Kelesidis, and M. E. Falagas Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence J. Antimicrob. Chemother., July 1, 2008; 62(1): 45 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Beceiro, F. Fernandez-Cuenca, A. Ribera, L. Martinez-Martinez, A. Pascual, J. Vila, J. Rodriguez-Bano, J. M. Cisneros, J. Pachon, G. Bou, et al. False extended-spectrum {beta}-lactamase detection in Acinetobacter spp. due to intrinsic susceptibility to clavulanic acid J. Antimicrob. Chemother., February 1, 2008; 61(2): 301 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Livermore The zeitgeist of resistance J. Antimicrob. Chemother., August 1, 2007; 60(suppl_1): i59 - i61. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Scheetz, C. Qi, J. R. Warren, M. J. Postelnick, T. Zembower, A. Obias, and G. A. Noskin In Vitro Activities of Various Antimicrobials Alone and in Combination with Tigecycline against Carbapenem-Intermediate or -Resistant Acinetobacter baumannii Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1621 - 1626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Insa, E. Cercenado, M. J. Goyanes, A. Morente, and E. Bouza In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia J. Antimicrob. Chemother., March 1, 2007; 59(3): 583 - 585. [Full Text] [PDF]
|
|
|
|
|
|
A. Y. Peleg, B. A. Potoski, R. Rea, J. Adams, J. Sethi, B. Capitano, S. Husain, E. J. Kwak, S. V. Bhat, and D. L. Paterson Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report J. Antimicrob. Chemother., January 1, 2007; 59(1): 128 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ng, I. B. Gosbell, J. A. Kelly, M. J. Boyle, and J. K. Ferguson Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review J. Antimicrob. Chemother., November 1, 2006; 58(5): 1078 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Seifert, D. Stefanik, and H. Wisplinghoff Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates J. Antimicrob. Chemother., November 1, 2006; 58(5): 1099 - 1100. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Coelho, J. F. Turton, M. E. Kaufmann, J. Glover, N. Woodford, M. Warner, M.-F. Palepou, R. Pike, T. L. Pitt, B. C. Patel, et al. Occurrence of Carbapenem-Resistant Acinetobacter baumannii Clones at Multiple Hospitals in London and Southeast England. J. Clin. Microbiol., October 1, 2006; 44(10): 3623 - 3627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Scheetz, K. M. Hurt, G. A. Noskin, and C. M. Oliphant Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens. Am. J. Health Syst. Pharm., July 15, 2006; 63(14): 1346 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Rodriguez-Hernandez, J. Saugar, F. Docobo-Perez, B. G. de la Torre, M. E. Pachon-Ibanez, A. Garcia-Curiel, F. Fernandez-Cuenca, D. Andreu, L. Rivas, and J. Pachon Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii J. Antimicrob. Chemother., July 1, 2006; 58(1): 95 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Saugar, M. J. Rodriguez-Hernandez, B. G. de la Torre, M. E. Pachon-Ibanez, M. Fernandez-Reyes, D. Andreu, J. Pachon, and L. Rivas Activity of Cecropin A-Melittin Hybrid Peptides against Colistin-Resistant Clinical Strains of Acinetobacter baumannii: Molecular Basis for the Differential Mechanisms of Action. Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1251 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Coelho, N. Woodford, M. Afzal-Shah, and D. Livermore Occurrence of OXA-58-Like Carbapenemases in Acinetobacter spp. Collected over 10 Years in Three Continents Antimicrob. Agents Chemother., February 1, 2006; 50(2): 756 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Knapp, C. W. Wieland, S. Florquin, R. Pantophlet, L. Dijkshoorn, N. Tshimbalanga, S. Akira, and T. van der Poll Differential Roles of CD14 and Toll-like Receptors 4and 2 in Murine Acinetobacter Pneumonia Am. J. Respir. Crit. Care Med., January 1, 2006; 173(1): 122 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Breedt, J. Teras, J. Gardovskis, F. J. Maritz, T. Vaasna, D. P. Ross, M. Gioud-Paquet, N. Dartois, E. J. Ellis-Grosse, E. Loh, et al. Safety and Efficacy of Tigecycline in Treatment of Skin and Skin Structure Infections: Results of a Double-Blind Phase 3 Comparison Study with Vancomycin-Aztreonam Antimicrob. Agents Chemother., November 1, 2005; 49(11): 4658 - 4666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Livermore Tigecycline: what is it, and where should it be used? J. Antimicrob. Chemother., October 1, 2005; 56(4): 611 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Pankey Tigecycline J. Antimicrob. Chemother., September 1, 2005; 56(3): 470 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Pachon-Ibanez, M. E. Jimenez-Mejias, C. Pichardo, A. C. Llanos, and J. Pachon Activity of Tigecycline (GAR-936) against Acinetobacter baumannii Strains, Including Those Resistant to Imipenem Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4479 - 4481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Higgins, H. Wisplinghoff, D. Stefanik, and H. Seifert In Vitro Activities of the {beta}-Lactamase Inhibitors Clavulanic Acid, Sulbactam, and Tazobactam Alone or in Combination with {beta}-Lactams against Epidemiologically Characterized Multidrug-Resistant Acinetobacter baumannii Strains Antimicrob. Agents Chemother., May 1, 2004; 48(5): 1586 - 1592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mushtaq, Y. Ge, and D. M. Livermore Comparative Activities of Doripenem versus Isolates, Mutants, and Transconjugants of Enterobacteriaceae and Acinetobacter spp. with Characterized {beta}-Lactamases Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1313 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ribera, F. Fernandez-Cuenca, A. Beceiro, G. Bou, L. Martinez-Martinez, A. Pascual, J. M. Cisneros, J. Rodriguez-Bano, J. Pachon, and J. Vila Antimicrobial Susceptibility and Mechanisms of Resistance to Quinolones and {beta}-Lactams in Acinetobacter Genospecies 3 Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1430 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Segal, E. C. Nelson, and B. G. Elisha Genetic Environment and Transcription of ampC in an Acinetobacter baumannii Clinical Isolate Antimicrob. Agents Chemother., February 1, 2004; 48(2): 612 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Spence, T. J. K. van der Reijden, L. Dijkshoorn, and K. J. Towner Comparison of Acinetobacter baumannii Isolates from United Kingdom Hospitals with Predominant Northern European Genotypes by Amplified-Fragment Length Polymorphism Analysis J. Clin. Microbiol., February 1, 2004; 42(2): 832 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Milatovic, F.-J. Schmitz, J. Verhoef, and A. C. Fluit Activities of the Glycylcycline Tigecycline (GAR-936) against 1,924 Recent European Clinical Bacterial Isolates Antimicrob. Agents Chemother., January 1, 2003; 47(1): 400 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Towner, T. Gee, and T. Boswell An unwanted import to the UK: a carbapenem-resistant clinical isolate of Acinetobacter baumannii producing metallo-{beta}-lactamase J. Antimicrob. Chemother., December 1, 2002; 50(6): 1092 - 1093. [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. SPENCE, K. J. TOWNER, C. J. HENWOOD, D. JAMES, N. WOODFORD, and D. M. LIVERMORE Population structure and antibiotic resistance of Acinetobacter DNA group 2 and 13TU isolates from hospitals in the UK J. Med. Microbiol., December 1, 2002; 51(12): 1107 - 1112. [Abstract] [Full Text] [PDF]
|
|